slide1 n.
Skip this Video
Download Presentation
Our Approach to Building a Company January 2012

Loading in 2 Seconds...

play fullscreen
1 / 19

Our Approach to Building a Company January 2012 - PowerPoint PPT Presentation

  • Uploaded on

Our Approach to Building a Company January 2012. Safe Harbor Statement.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Our Approach to Building a Company January 2012' - dalton-little

Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Safe Harbor Statement

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, factors related to GenSpera’s anticipated growth strategies, future business development, ability to attract and retain new clients, ability to develop new products, expand to other related industries or markets in other geographical locations, and other information detailed from time to time in the filings and future filings with the United States Securities and Exchange Commission.  Readers are advised that this information is intended for the use of investment professionals.  Anyone interested in obtaining information on GenSpera should contact GenSpera, as set forth above, to receive GenSpera’s most recent financial reports.  This presentation was developed by GenSpera and is intended solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy the Company’s stock.  This profile is based upon information available to the public, as well as other information from sources which management believes to be reliable, but is not guaranteed by the Company as being accurate nor does it purport to be complete. Opinions expressed herein are those of management as of the date of publication and are subject to change without notice. 


GenSpera’s Breakthrough Technology

Traditional chemotherapy features:

  • Targets cell division
  • Typified by side effects, drug resistance
  • Little effect on slow growing tumors or cancer stem cells
  • Just doesn’t work well enough

Our “molecular grenade” features are a major breakthrough:

  • Kills independent of cell division rate (kills slow-growing tumors and stem cells)
  • Targeted delivery specifically to tumors (minimize side effects, maximize efficacy)
  • No development of drug resistance
  • Complete tumor regression observed in multiple preclinical animal studies

How Our Molecular Grenades Work

…until it finds an “enzyme” (tumor marker), which is found only at our “target site,” that “pulls the pin on the grenade” off the targeting/masking agent.

Our active drug, with a targeting/masking agent attached, i.e., the prodrug, is inactivein the blood stream – similar to a grenade with an intact pin…


(or blood vessel of tumors)


The activedrug, no longer soluble, “precipitates” directly into nearby cells and kills them.


Thapsigargin – A Novel Cytotoxin

Isolated from seeds of Thapsia garganica

100 kg seeds yields ~1 kg of thapsigargin

Potent inhibitor of ER Ca2+ ATPase pump

Kills cancer cells independent of growth rate

Isolatedfrom seeds of Thapsia garganica

100 kg seeds yields ~1 kg of thapsigargin

Potent inhibitor of ER Ca2+ ATPase pump

Kills cancer cells independently of growth rate


How We Make G-202





Delivered to Tumor

Peptide Attached

  • Derived from Mediterranean plant (exclusive supply agreements)
  • Well-characterized and studied
  • Kills:
    • Slow- and fast-growing cancer cells
    • Cancer stem cells
    • Established vascular cells
  • Patent-protected*
  • Peptide attached to 12ADT
  • Renders 12ADT:
    • Inactive
    • Soluble
    • Targets tumor
  • Intravenous application
  • Patent-protected*

Peptide removed by enzyme PSMA at the target site

* 9 patents & 4 patent applications; no milestone or royalty payments are owed


Recent achievements:

  • Phase I program is ongoing at CTRC, Johns Hopkins and Univ Wisconsin
  • G-202 exposure in patients is at levels expected to show efficacy
  • Second cGMP clinical batch of G-202 is in use

Near-term milestones:

  • Continued enrollment and dose-escalation in G-202 Phase I
  • Initiate Phase Ib post-chemotherapy prostate cancer study
  • Initiate Phase II castrate-resistant chemotherapy-naïve prostate cancer study in US and UK
  • Plan to start two other Phase II studies in 2012 and early 2013

Achievements and Milestones

why start a company
Without a stand alone company, this great technology likely won’t be developed any other way.

Perceived development issues

Immature technology at the time

Scientific prejudice

Similar approaches at other companies had failed

Why start a company?
time and costs for drug development
1Time and Costs for Drug Development

Drug development takes too much time, needs too much money and has too much risk.

VCs no longer invest before Phase II.

But drugs with Phase II activity can be worth $1B!!!

Need a new model to attract investors.

genspera s initial value proposition
Investors want upside, timeliness and liquidity.

GenSpera offers:

Reasonable entry price

Possible 60-fold return on investment within 5-6 years

Likelihood of steadily increasing valuations

Liquidity via public listing on OTCBB

GenSpera’s Initial Value Proposition

GenSpera Financing 2007

  • Identified successful financing approach
  • Recruited a team using stock awards
  • Rewrote the business plan
  • Identified investors (19 of 22 invested)


  • Be flexible
  • Listen and learn
  • Build a great team
  • Know your potential investors
  • Don’t be greedy
  • Communicate your vision

GenSpera Financing 2008

  • Used investment banker to lead the round
  • Went to raise $5M, only brought in $2.3M
  • Expanded investor base to West Coast


  • Tough to raise money in difficult markets
  • Run your company as if money will always be scarce
  • Plan and execute

GenSpera Financings 2009 – 2011


  • Almost all new investors were introduced by previous investors

2010, 2011

  • >90% of monies raised came from previous investors


  • Investors are important team members
  • Keep your investors engaged
  • Plan and execute

Location of GenSpera Investors




















life as an entrepreneur
Takes real commitment and hard work

Can be incredibly frustrating, especially at the beginning

Requires flexibility and constant learning

Can be incredibly rewarding

Opportunity to create something with real impact

Opportunity to work with fantastic people of varying backgrounds and expertise

Life as an Entrepreneur
advice for entrepreneurs
Personal integrity and honesty are your greatest assets.

Communicate your vision.

Build a great team.

Listen carefully and have an open mind.

Keep it simple. Stay organized. Stay focused.

Read the fine print. Do diligence on your potential investors.

Plan and execute.

Respect the money.

Advice for Entrepreneurs


Craig A. Dionne, PhD

President and CEO

GenSpera, Inc.

2511 N Loop 1604 W, Suite 204

 San Antonio, TX 78258

Phone: (210) 479-8112

Fax: (210) 479-8113